Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANORAMA: Vedolizumab in Ulcerative Colitis and Crohn's Disease
NCT06581328Phase 4Recruiting
- Sponsor
- Takeda
- Start
- Mar 2025
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of vedolizumab in ulcerative colitis (UC), Crohn's disease, sponsored by Takeda. Started Mar 2025; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT06581328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581328.